Recombinant virus for preventing viral myocarditis as well as vaccine and applications tof recombinant virus

A technology of recombinant virus and stomatitis virus, applied in the direction of antiviral agent, virus/phage, recombinant DNA technology, etc., can solve the problem of poor effect of viral myocarditis, achieve prevention of viral myocarditis, enhance induction, improve viral Myocarditis effect

Active Publication Date: 2014-06-18
SUZHOU UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The object of the present invention is to provide a kind of recombinant virus for preventing viral myocarditis and its vaccine and application, and described this kind of recombinant virus for preventing viral

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant virus for preventing viral myocarditis as well as vaccine and applications tof recombinant virus
  • Recombinant virus for preventing viral myocarditis as well as vaccine and applications tof recombinant virus
  • Recombinant virus for preventing viral myocarditis as well as vaccine and applications tof recombinant virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Hela cell culture and CVB3 virus passage:

[0042] The human cervical cancer cell line Hela cell of the present invention is cultivated according to a conventional method, with RPMI-1640 medium containing 10% NBS, 2mM L-glutamine, 100U / ml penicillin and kanamycin sulfate at 37°C, 5% CO 2 cultured under the same conditions and passaged every other day. Infect about 5×10 6 Hela cells, after 40 hours of culture, 80% of the cells were lysed by the replicating virus, and the liquid and cell debris were centrifuged at 3000 rpm / min for 20 minutes, and the obtained supernatant was fresh CVB3 suspension.

Embodiment 2

[0043] LD of embodiment 2 CVB3 virus 50 (LD50) titration:

[0044] BALB / c suckling mice born for 48 hours were taken out and divided into 8 groups with 6 mice in each group. -1 、10 -2 、10 -3 、10 -4 、10 -5 、10 -6 、10 -7 、10 -8 , respectively take 100 μl and inject 8 groups of suckling mice through intraperitoneal cavity, observe the survival situation of suckling mice every day, and calculate the LD of this batch of CVB3 virus according to the routine method of virology 50 potency. Distance ratio = (>50% death percentage - 50) / (>50% death percentage - 50 => 50% of the logarithm of the mortality dilution (Log) + distance ratio

[0045] LD of CVB3 in the same batch in this test 50 Valence is 10 -5.5 / 100ul.

Embodiment 3

[0046] Example 3 Construction of recombinant VSV virus and identification of expression function in vitro

[0047] 1 Construction of the target antigen plasmid pXN2-VP1: the pXN2-VP1 plasmid with pXN2 as the carrier was constructed with the CVB3 structural protein VP1 as the target antigen. Wherein, the VP1 cDNA sequence is based on literature (Klump WM, et al. J Virol, 1990, 64(4):1573-1583), specifically shown in SEQ ID NO:1.

[0048] 1) The CVB3VP1 gene was obtained from freshly cultured CVB3 (Nancy strain) by RT-PCR.

[0049] Design the upstream and downstream primers of VP1: KV1: 5′-CCCAAGCTTGCCACCATGGGCCCAGTG GAAGACGCG-3′; KV2: 5′-CGGGATCCTTACTAAAATGCGCCCGTA TTTGT C-3′. Viral RNA was extracted according to the RNAex Reagent&System Kit of Shanghai Huashun Biological Company, and the total RNA of CVB3 was mixed with 20 μl DEPC H 2 dissolved in O and stored at -80°C.

[0050] The reverse transcription of cDNA was carried out according to the 2-N First Strand cDNA Synthes...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a recombinant virus. A vesicular stomatitis virus serves as a carrier, and an encoded antibody CVB3 structural protein VP1 gene is inserted between glycoprotein G and polymerase protein L of the vesicular stomatitis virus. The invention also provides a preparation method of the recombinant virus. According to the method, the recombinant virus is obtained by means of transfecting BHK21 cells via five plasmids: pP, pL, pXN2-VP1, pVSVG and pN. The invention also provides a vaccine which contains an effective dose of vaccine contains. A person can be vaccinated with the vaccine in a mucosa part by means of nasally dripping or orally taking, or through genital tracts, and the like. The technical problems is as follows: the conventional vaccine in the prior art can not effectively induce high-strength mucosa immune response, and the antibody can not effectively stay at a local mucosa part and consequently is insufficiently taken by APCs (Antigen Presenting Cells) are solved. The recombinant virus is capable of effectively enhancing CVB3 specific serum and local mucosa part antibody response, and remarkably strengthening the killing capability to local specific CD8T cells of whole-body and intestinal mucosa.

Description

Technical field: [0001] The invention relates to biological gene technology, in particular to a recombinant virus, in particular to a recombinant virus for preventing viral myocarditis and its vaccine and application. Background technique [0002] Viral myocarditis is mainly caused by Coxsackie virus type B3 (CVB3) infection, and the incidence is higher in young adults, which can cause about 50% of human acute and chronic myocarditis and 25% of dilated cardiomyopathy. It is a common and frequently occurring disease. diseases of the cardiovascular system. There is currently no effective preventive or therapeutic vaccine. CVB3 belongs to enterovirus. After invading the body through the respiratory tract and gastrointestinal tract, the body's mucosal immunity (such as intestinal IgA) cannot clear the virus in the early stage of infection, so the virus quickly spreads into the blood and then invades the heart, resulting in viral myocarditis; Persistent infection of CVB3 may al...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N7/01C12N15/86A61K48/00A61K39/125A61P31/14A61P9/00C12R1/93
Inventor 熊思东董春升徐薇吴飞
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap